SLC5A2 and type 2 diabetes mellitus: The VBA in the UK, contracted with a clinical commissioning group (CCG), was for dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus (T2DM).